Clinical Trial Update: Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3) [Phase 1, Phase 2]

View source ↗

Summary

Dizal Pharmaceuticals has withdrawn the Phase 1/2 trial of the oral BTK inhibitor DZD9008 in non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• DZD9008

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Non-Hodgkin's B-cell Lymphoma | Phase 1, Phase 2 | Status: WITHDRAWN